Powered by Smartsupp

Memory, dementia and photobiomodulation: can light help?

KINGRAY Academy logo
KINGRAY ACADEMY
LASER SERIES · 06

Is your memory getting worse, or are you looking for information for someone with dementia? Photobiomodulation investigates whether precisely applied light can influence brain function. Some clinical studies have reported encouraging results; others have not confirmed a benefit. It matters who received the light, how it was delivered and what actually improved. [3][4][5][6][7]

Select a question to scroll to its answer within this article.

Author: Ing. František Kokoš
Updated:

When is forgetfulness more than a normal age-related change?

Occasionally searching for a word differs from repeatedly becoming disoriented or struggling with familiar activities. Dementia is a syndrome in which declining cognitive abilities interfere with everyday independence. It is neither a single disease nor an inevitable consequence of ageing. [1]

Alzheimer’s disease is the most common cause of dementia. Vascular dementia involves damage to brain vessels; Lewy body dementia and frontotemporal dementia involve different pathological processes. Several causes can coexist. We therefore cannot explain every memory disorder as “thick blood” or expect the same response to one method. [1]

In mild cognitive impairment, or MCI, difficulties exceed typical age-related changes, but independence remains largely preserved. MCI does not necessarily mean Alzheimer’s disease and does not always progress to dementia. Results in MCI therefore cannot automatically be transferred to advanced disease. [2]

What changes should families notice, and how is memory assessed?

Does the person ask the same question without remembering the answer? Do they get lost in familiar places or struggle with medication, bills or their usual cooking? These concrete examples help a clinician more than the label ‘poor memory’. Assessment may include validated tests; MoCA and MMSE often appear in clinical trials. Language, education, vision and hearing can affect results. No single score confirms or excludes dementia on its own. [8]

Clinicians also assess language, planning, changes in mood, behaviour and sleep. They investigate other possible causes, including medicines, depression or physical illness. Sudden confusion developing over hours or days is not normal ageing and needs prompt medical assessment. Sudden speech difficulty or weakness on one side requires emergency medical help. [1][8][18]

Why can childhood memories remain while recent events are forgotten?

Typical Alzheimer’s disease may affect the formation of new episodic memories early: what happened today or what the last conversation was about. Frequently recalled older experiences, familiar songs and some practised skills may remain accessible longer. There is no fixed sequence of memory loss. In other dementias, changes in behaviour, language or spatial orientation may be more prominent initially. [1][9]

What supports memory alongside research into light?

Age is a major risk factor, but dementia is not an inevitable part of ageing. Suitable physical activity, social contact, meaningful activities and care for hearing, blood pressure, cholesterol and diabetes are important areas of prevention and support. In diagnosed dementia, activities and family assistance can support functioning and quality of life. Reducing the risk of developing disease and slowing established disease are different outcomes. [10]

How can light pass through the skull?

Transcranial PBM applies light externally to the head. Some radiation is reflected, absorbed or scattered; some may penetrate deeper. Jagdeo and colleagues demonstrated transmission of 830 nm through head tissues in a cadaveric model, greater under those conditions than at 633 nm. The dose in a living brain also depends on hair, skin, bone, application site and source geometry. Power at the surface is not the dose throughout the brain. [11][17]

Why are researchers studying light and the brain?

Nerve cells need energy in the form of ATP, a supply of oxygen and nutrients, and functioning connections with other cells. Photobiomodulation, or PBM, research examines responses to red or near-infrared light: mitochondrial processes, cellular signalling, the inflammatory environment and vascular responses. [3]

A biologically plausible mechanism is a starting point for research. A change in a cell or animal model does not establish that a person will communicate better, remember medication or live more independently. Those conclusions require clinical trials with an appropriate control group. [3][4][5][6][7]

One proposed mechanism involves cytochrome c oxidase, an enzyme in the mitochondrial respiratory chain. Researchers also investigate nitric oxide, vascular responses and cellular signalling. Mechanisms depend on conditions; it cannot be assumed that every light exposure automatically increases ATP in all neurons. [3]

In 2023, Fear and colleagues used phosphorus magnetic resonance spectroscopy to observe a change in flux associated with ATP synthesis after 670 nm exposure; seven older adults were analysed. This small study without a parallel control group provides interesting biological evidence, rather than proof of a dementia treatment. [12]

What do we know about amyloid and inflammation in the brain?

In 2014, Purushothuman and colleagues studied two genetic mouse models. Light application reduced the number and size of plaques in the amyloid model; markers of tau and oxidative stress changed in the other model. This supports further investigation of mechanisms, but it is not a finding in humans. [13]

A better MoCA or MMSE score does not itself show amyloid removal. Demonstrating that effect in humans requires appropriate biomarkers and sound clinical follow-up. The studies discussed do not establish that a home device reverses brain damage or stops Alzheimer’s disease. [5][6][7][13]

Wavelength and 40 Hz: two different quantities

Nanometres describe wavelength; hertz describes pulses per second. Brain studies use, for example, 808, 810 or 1064 nm. Effects also depend on power per area, duration, location and pulse settings. Current findings do not identify one best colour or frequency for everyone with dementia. [3][5][6][17]

In 40 Hz sensory stimulation, a person views flickering light, often accompanied by sound; the aim is to influence brain rhythms through the senses. Chan and colleagues studied this approach in people with mild Alzheimer’s dementia. It differs from transcranial PBM, even when a PBM device also pulses at 40 Hz. Findings cannot automatically be transferred between them. [14]

What did the early observations show?

In 2017, Saltmarche and colleagues followed five people with dementia or possible Alzheimer’s disease. For 12 weeks, they combined transcranial application through the head with intranasal application at 810 nm. Mean MMSE scores increased by 2.6 points and ADAS-cog scores decreased by 6.73 points; both directions indicate better test performance. [4]

Families also reported changes in sleep, communication and behaviour. However, there was no control group, and post-withdrawal data were incomplete. Five cases provide a reason for further investigation, rather than a reliable estimate of benefit for every patient. The combined treatment results cannot be attributed to the nasal component alone. [4]

Newer studies: positive and neutral findings

Chun and colleagues, 2026: 80 participants with MCI

A randomised, blinded study in MCI due to Alzheimer’s disease examined transcranial 808 nm light over 12 weeks. Mean MoCA-K scores increased by 3.87 points in the active group and decreased by 0.74 points in the control group. This is a positive result for a specific protocol, not proof that future dementia was prevented. [5]

Rashidi-Ranjbar and colleagues, 2026: a 20-participant pilot

After six weeks of transcranial 810 nm application, the researchers reported favourable changes in some cognitive, metabolic and imaging measures. The small sample and multiple outcomes call for caution. Changes in blood metabolites do not directly measure ATP in neurons. [6]

Jarrahi and colleagues, 2025: 30 people with dementia

In mild-to-moderate dementia, standard care plus PBM was compared with the same care plus an inactive device. No between-group benefit in cognition, depression or anxiety was demonstrated immediately after treatment or at the one-month follow-up. This regimen therefore did not confirm the anticipated benefit. [7]

Does MCI differ from advanced dementia?

Yes. MCI does not always mean Alzheimer’s disease, and many people remain largely independent. Advanced dementia involves different needs and a different extent of damage. Encouraging results in selected MCI patients therefore do not predict an effect in someone with severe dementia. Studies also need to assess independence, caregiver burden and the durability of any benefit. [2][5][7]

Why does the application route matter?

Transcranial light passes through tissues of the head. A nasal applicator illuminates the nasal mucosa. A combined protocol uses both routes. The illuminated areas, light attenuation and dose in the target tissue differ. The same wavelength therefore does not mean the same effect. [3][4]

When assessing a study, consider the diagnosis, disease stage, application site, light parameters, follow-up period and control group. A small positive trial does not define universal home-use dosing or prove the effectiveness of every device labelled PBM. [3][4][5][6][7]

What matters to the person and their family?

Relevant outcomes include orientation, conversation, sleep, everyday tasks and the need for assistance. Adverse effects, reliable use and the duration of any benefit also need monitoring. A home device does not automatically make caring for someone with dementia straightforward. [4]

New or worsening difficulties deserve assessment. Medicines, depression, deficiencies in certain nutrients and other conditions can also contribute to memory problems. An experimental method should not delay identifying the cause or replace prescribed care. [1][2]

Safety: eyes, heat, pulsing and supervision

The 80-participant study reported no device-related adverse events; the 20-participant pilot recorded adverse events in both groups, with no serious events. This does not make every device risk-free. Its parameters, eye protection and intended use matter. Do not look into a beam, and follow the manufacturer’s protective measures; excessive exposure can injure eyes or overheat tissue. [5][6][15][17]

With epilepsy, medicines that increase light sensitivity or skin disease at the application site, discuss the specific procedure with a clinician beforehand. Visible flicker can trigger seizures in photosensitive people. Invisible NIR pulses applied to the head cannot automatically be equated with that visual stimulus, but neither can every protocol be declared safe. A person with dementia may need a caregiver’s supervision. [16][17]

What did the studied home schedules involve?

Chun and colleagues applied 808 nm six times weekly for 12 weeks, with the primary assessment at week 13. The Rashidi-Ranjbar pilot used 810 nm for 20 minutes, six days per week for six weeks. These describe research protocols, not instructions for another device or a dose recommendation for an individual patient. [5][6]

The schedule must suit the device and the person’s health. Longer exposure does not automatically produce a better result. Any benefit should be evaluated through repeated professional assessment alongside daily functioning, rather than an impression after one session. Do not change treatment without discussing it with a clinician or delay diagnosis. [8][17]

Frequently asked questions

Can red light cure Alzheimer’s disease?

The studies discussed here do not establish this. They investigate specific protocols and outcomes, rather than providing general proof of a cure or halted neurodegeneration. [4][5][6][7]

Do findings in MCI also apply to advanced dementia?

Not automatically. Causes, the extent of damage and remaining abilities differ. Each population needs its own clinical evidence. [1][2][5]

Does combined head and nasal treatment prove the effectiveness of nasal treatment alone?

No. Separate comparison groups are needed to distinguish the contribution of each component. [4]

When is forgetfulness normal, and when could it indicate dementia?

Change from previous functioning matters. Repeatedly getting lost or struggling with familiar tasks deserves assessment; occasionally forgetting a name does not establish a diagnosis. [1][8]

Which warning signs and tests help identify early dementia?

Repeated questions, orientation, medication management and everyday responsibilities are relevant. A cognitive test is only part of an assessment; even a normal score cannot rule out dementia by itself. [8]

Which types of memory change first, and which may remain intact longer?

Learning new events is often affected early in typical Alzheimer’s disease. Older memories and practised skills may last longer, but the pattern varies between individuals. [1][9]

What changes in language, behaviour, orientation and sleep can accompany dementia?

Difficulties finding words, planning, orientation, mood or sleep may occur. Sudden confusion requires prompt medical assessment. [1][8][18]

How do age, lifestyle and social isolation relate to memory health?

Age increases risk, but dementia is not inevitable. Movement, social contact and managing vascular risks support health; they do not guarantee that established disease will stop. [10]

What is brain photobiomodulation, and how does light pass through the skull?

Transcranial PBM applies light to the head. Some penetrates tissue and some is absorbed or scattered. Penetration alone does not demonstrate an effective dose throughout the brain. [11][17]

What can light influence in mitochondria and the brain’s energy metabolism?

Researchers study mitochondrial enzymes, ATP metabolism and vascular signalling. Measuring energy metabolism does not by itself prove improved memory in an individual patient. [3][12]

Can photobiomodulation reduce amyloid plaques?

Reduced amyloid plaques have been observed in some mouse models. The human clinical studies discussed here do not demonstrate that home PBM clears amyloid from the brain. [5][6][7][13]

Which wavelengths are being studied, and what does pulsing at 40 Hz mean?

Research uses, for example, 808, 810 and 1064 nm. There is no established best universal protocol. Pulsed PBM and visible light flickering with sound at 40 Hz are different approaches. [3][5][6][14][17]

Can photobiomodulation cure Alzheimer’s disease or relieve its symptoms?

The studies discussed have not demonstrated a cure or disease arrest. Some protocols improved cognitive scores, while others did not show benefit. [4][5][6][7]

What have clinical studies in people with MCI and dementia found?

MCI studies published in 2026 reported encouraging results. A dementia trial published in 2025 was neutral. Diagnosis, protocol, controls and follow-up all matter. [5][6][7]

How does application through the head differ from an intranasal applicator?

The application site and tissue dose differ. A positive result from combined head and nasal application does not separate the contribution of each component. [3][4]

Are results in MCI the same as in advanced dementia?

This has not been established. MCI and advanced dementia differ in severity and causes; results in one group cannot automatically be transferred to the other. [2][5][7]

Which risks and limitations matter when using a device at home?

Eye protection, heating, skin condition and device instructions need consideration. Epilepsy or photosensitivity requires individual assessment; visible flicker presents a distinct risk. [5][6][15][16][17]

How often and for how long is PBM studied, and when can outcomes be assessed?

Studies have used different schedules over weeks to months. A research schedule is not a universal instruction and cannot predict when an individual’s memory will improve. [5][6][17]

Sources and research

Based on source material by Ing. František Kokoš and additional research sources. Updated 10 November 2026. Studies [5]–[7] are summarised from their published abstracts. Animal findings, biological measurements and human clinical outcomes are distinguished.

  1. National Institute on Aging. What Is Dementia? Symptoms, Types, and Diagnosis.
    Open source ↗
  2. National Institute on Aging. What Is Mild Cognitive Impairment?
    Open source ↗
  3. Salehpour F et al. Brain Photobiomodulation Therapy: a Narrative Review. Molecular Neurobiology. 2018;55:6601–6636. DOI: 10.1007/s12035-017-0852-4.
    Open source ↗
  4. Saltmarche AE et al. Significant Improvement in Cognition in Mild to Moderately Severe Dementia Cases Treated with Transcranial Plus Intranasal Photobiomodulation: Case Series Report. Photomed Laser Surg. 2017;35:432–441. DOI: 10.1089/pho.2016.4227.
    Open source ↗
  5. Chun H et al. Home-based transcranial photobiomodulation improves cognitive function in mild cognitive impairment due to Alzheimer’s disease: A randomized, double-blind, placebo-controlled confirmatory trial. J Alzheimers Dis. 2026;111:1699–1707. DOI: 10.1177/13872877261443973.
    Open source ↗
  6. Rashidi-Ranjbar N et al. A multimodal evaluation of transcranial photobiomodulation in mild cognitive impairment: Cognitive, metabolic, and neuroimaging outcomes of a pilot randomized controlled trial. J Alzheimers Dis. 2026;112:1445–1458. DOI: 10.1177/13872877261453911.
    Open source ↗
  7. Jarrahi S et al. The Efficacy of Photobiomodulation Therapy in Improving Cognitive Function and Reducing Depression and Anxiety in Patients with Mild-to-Moderate Dementia: A Double-Blinded Randomized Clinical Trial. Photobiomodul Photomed Laser Surg. 2025;43:585–591. DOI: 10.1177/25785478251376443.
    Open source ↗
  8. NICE. Dementia: assessment, management and support for people living with dementia and their carers. NG97, recommendations.
    Open source ↗
  9. Alzheimer’s Society. Memory loss and dementia.
    Open source ↗
  10. World Health Organization. Dementia. 26 October 2026.
    Open source ↗
  11. Jagdeo JR et al. Transcranial Red and Near Infrared Light Transmission in a Cadaveric Model. PLoS ONE. 2012;7:e47460. DOI: 10.1371/journal.pone.0047460.
    Open source ↗
  12. Fear EJ et al. Use of 31P magnetisation transfer magnetic resonance spectroscopy to measure ATP changes after 670 nm transcranial photobiomodulation in older adults. Aging Cell. 2023;22:e14005. DOI: 10.1111/acel.14005.
    Open source ↗
  13. Purushothuman S et al. Photobiomodulation with near infrared light mitigates Alzheimer’s disease-related pathology in cerebral cortex – evidence from two transgenic mouse models. Alzheimer’s Research & Therapy. 2014;6:2. DOI: 10.1186/alzrt232.
    Open source ↗
  14. Chan D et al. Gamma frequency sensory stimulation in mild probable Alzheimer’s dementia patients: Results of feasibility and pilot studies. PLoS ONE. 2022;17:e0278412. DOI: 10.1371/journal.pone.0278412.
    Open source ↗
  15. U.S. Food and Drug Administration. Frequently Asked Questions About Lasers.
    Open source ↗
  16. Epilepsy Society. Photosensitive epilepsy.
    Open source ↗
  17. Zein R, Selting W, Hamblin MR. Review of light parameters and photobiomodulation efficacy: dive into complexity. Journal of Biomedical Optics. 2018;23:120901. DOI: 10.1117/1.JBO.23.12.120901.
    Open source ↗
  18. NHS. Sudden confusion (delirium).
    Open source ↗
Ing. František Kokoš
Author: Ing. František Kokoš
Ing. František Kokoš – Author of KINGRAY Academy and Advice Corner
Technician, nutrition adviser (graduate of the 150-hour Welko retraining programme, 2025) and creator of the KINGRAY nutraceuticals concept. Years of developing the BIOquant medical device and working with blood rheology and tissue oxygenation led him to realise that bodily health requires the full picture – linking microcirculation, cellular energy and proper nutrition. In his articles, he looks for the balance where the body understands and cooperates with us.
He is the author of the book Liečba svetlom (Light Therapy, ISBN 978-80-970512-0-4), co-author of the publication BIOquant – polovodičová laserová terapia (BIOquant – Semiconductor Laser Therapy, ISBN 978-80-970512-2-8), and originator of patents in light technologies (US9731145B2, SK5457Y1).
%s ...
%s
%image %title %code %s
%s